alose-anesthetized newborn pigs with closed cranial windows. Before treatment with indomethacin, arachidonic acid and hypercapnia dilated pial arterioles and increased cortical periarachnoid cerebrospinal fluid concentrations of 6-keto-prostaglandin (PG) F,, and PGE,. One h after indomethacin treatment, the dilations and prostanoid synthesis were blocked. By 2 h after indomethacin treatment, hypercapnia produced significant dilation of pial arterioles, and dilation to both stimuli had returned to ~reindometha-cin levels by 3 h. Inhibition of conversionAof exogenous arachidonic acid to prostanoids as monitored by increases in 6-keto-PGF,, and PGEz in cerebrospinal fluid under the window also was reversed by 3 h after treatment with indomethacin. Repeated indomethacin treatment again blocked dilations and conversion of arachidonic acid to prostanoids on the brain surface. The possibility of short duration of vascular effectiveness of indomethacin when it is administered systemically needs to be considered, both when it is used a s a probe for understanding contributions of P G H synthase products to control of cerebral circulation and when it is used therapeutically in attempts to alter the newborn cerebral circulation. (Pediatr Res 33: 609-614, 1993) crosses the blood brain barrier (I), and a dose of 5 mg/kg i.v. inhibits conversion to prostanoids of arachidonic acid applied topically to the parietal cortex of piglets (2) . In newborn pigs, such treatment with indomethacin also decreases cerebral blood flow (3) and blocks cerebral vasodilation in response to hypercapnia (4, 5) , hypotension (6) , and topically applied histamine (7) . These stimuli increase cortical periarachnoid CSF concentrations of prostanoids, suggesting a functional association between the vasodilation and the prostanoid synthesis.
Indomethacin is a reversible inhibitor of PGH synthase (8). Therefore, when tissue levels of indomethacin fall sufficiently, inhibition will be lost concomitantly. It is generally assumed that the duration of action of indomethacin is long, but the plasma half-life is relatively short, and the CSF concentration is closely related to that of plasma (I). We have observed that repeated doses are often necessary to maintain inhibition of responses, and Lozon et ul. (9) have reported that cerebral blood flow reactivity to hypercapnia in piglets returns by 2 h after treatment with 5 mg/kg of indomethacin.
The present experiments therefore examined, before and at progressive times after indomethacin, responses of pial arterioles to topically applied arachidonic acid and hypercapnia. The hypothesis addressed was that the return of responses to arachidonic acid and hypercapnia after indomethacin would coincide and both would again be lost after repeat indomethacin treatment.
MATERIALS AND METHODS

Abbreviations
Newborn ins ( 1 to 3 d old) were anesthetized with ketamine PG, prostaglandin P G H synthase, prostaglandin H synthase CSF, cerebrospinal fluid aCSF, artificial cerebrospinal fluid LT, leukotriene hydrochlorideu(33 mg/kg intramuscularly) and acepromazine (3.3 mg/kg intramuscularly) and maintained on a-chloralose (50 mg/kg i.v. initially, plus 5 mg. kg-'. h-I). The animals were intubated and ventilated with air. Catheters were inserted in the femoral vein for maintenance of anesthesia and blood withdrawal and in the femoral artery to record blood pressure and draw samples for blood gas and pH analysis. Body temperature was maintained between 37 and 38°C. The scalp was retracted, and Indomethacin is widely used as a tool to study contributions a hole 2 cm in diameter was made in the skull over the parietal of prostanoids to cerebral vascular control. Free indomethacin cortex. The dura was cut without touching the brain, and all cut edges were retracted over the bone so that the periarachnoid Pial arterioles 40 to 150 Fm in diameter were observed with a dissecting microscope. Diameters were measured with video micrometer coupled to a television camera mounted on the microscope and a video monitor.
Measurement of Microvascular Responses. Arachidonic acid. Windows were flushed with aCSF, and control measurements of pial arteriolar diameter, arterial blood pressure, blood gases, and pH were taken. After 10 min, cortical periarachnoid fluid was collected for prostanoid analysis, and arachidonic acid was then applied at 2 mg/L (in aCSF). Measurements of pial arteriolar diameter were made for 10 min, and the aCSF was collected for prostanoid analysis. Arachidonic acid at 20 mg/L then was applied similarly.
Hypercapnia. After flushing the window with aCSF, control measurements of pial arteriolar diameter, arterial blood pressure, blood gases, and pH were taken. Hypercapnia was produced by ventilating with a 10% COZ, 21% OZ, and 69% Nz mixture. Pial arteriolar diameter and arterial pressure were measured. After 10 min of hypercapnia, cortical periarachnoid fluid was collected, and an arterial blood sample for blood gases and pH analysis was drawn.
Experimental Design. The experimental design consisted of initial measurements and treatments (arachidonic acid or hypercapnia), administration of indomethacin, repeated measurements and treatments over 3 h, and then a repeat administration ofindomethacin. After indomethacin trihydrate (gift from Merck Sharp and Dohme Research Laboratories, Rahway, NJ) (5 mg/ kg, i.v.) was administered, 45 min were allowed to pass before examinations of responses to arachidonic acid or hypercapnia were repeated. Five mg/kg of indomethacin were used in these experiments because previous experiments (2) showed that this dose effectively inhibits conversion of topical arachidonic acid to prostanoids on the brain surface and blocks vasodilation to hypercapnia. The 45-min period before resuming experiments was allowed, because we know from previous experiments that dilations to both exogenous arachidonic acid and hypercapnia were inhibited at about this time (2, 4, 5) . Treatments (arachidonic acid or hypercapnia) were given at 1, 2, and 3 h after indomethacin. Then a second administration of indomethacin was given and, 30 min later, a final control period and treatment with either arachidonic acid or hypercapnia was carried out.
The animal protocols were reviewed and approved by the Animal Care and Use Committee of the University of Tennessee, Memphis. Measurement of Prostanoids. In cortical periarachnoid CSF, 6-keto-PGF,,, and PGEz were analyzed by RIA against an aCSF matrix as described previously (13) . All unknowns were processed at three dilutions, with parallelism between the unknown dilution curve and the standard curve required before the result was used. Sample dilutions allowed analysis of 6-keto-PGF,, and PGE2 concentrations between 100 and 50 000 ng/L. Nondetectable levels were recorded as 50 ng/L and values greater than 50 000 ng/L as 50 000 ng/L for statistical purposes. Our antibodies cross-react minimally (< 1 %) with PGFZ,,, thromboxane B?, and PGDr. Furthermore Comparisons among populations used analysis of variance with repeated measures. Fisher protected least significant difference was used to determine differences between groups. p < 0.05 was required for inference that populations were different.
RESULTS
The effects of indomethacin on pial arteriolar responses to topical arachidonic acid are shown in Table 1 The residual high levels are probably the result of previous synthesis, because we have found before that, if the cranial window is flushed with aCSF repeatedly after indomethacin treatment, prostanoid concentrations in cortical periarachnoid CSF will be at nondetectable levels by 45 min (2, 4). The reductions in resting levels of CSF 6-keto-PGF,, and PGE2 were sustained at 2 and 3 h posttreatment (256 k 102 and 128 + 40 ng/L for 6-keto-PGF,, and 472 +-99 and 629 f 186 for PGE2, ng/L, respectively). However, inhibition of conversion of exogenous arachidonic acid to prostanoids was not sustained for the 3-h period. Instead, the time course of inhibition of conversion of arachidonic acid to prostanoids as monitored by 6-keto-PGE,, and PGE2 concentrations in CSF under the cranial windows was similar to the time course of inhibition of vasodilation to arachidonic acid by indomethacin (Figs. 2 and 3) . Thus, 1 h after indomethacin treatment, conversion of exogenous arachidonic acid to 6-keto-PGF,, and PGE2 was minimal. By 2 h, small but significant conversion occurred, and by 3 h, the fractional increases in prostanoids after application of arachidonic acid were the same as before indomethacin treatment. The absolute levels of prostanoids achieved, on the other hand, remained reduced even 3 h after indomethacin compared with before indomethacin Table 2) . Before indomethacin treatment, this level of hypercapnia produced dilation of pial arterioles of 54 f 4%. Indomethacin treatment totally abolished the vasodilation in response to hypercapnia administered approximately I h after indomethacin treatment. By 2 h after treatment, significant vasodilation was produced by hypercapnia (27 +-4%) that remained reduced compared with pretreatment dilation. Three h after indomethacin treatment, vasodilation of pial arterioles in response to hypercapnia (52 + 4%) was identical to that seen before indomethacin treatment. This vasodilation was again totally abolished by repeat treatment with indomethacin. Although hypercapnic vasodilation had returned by 3 h after indomethacin, we were unable to detect significant return of cerebral prostanoid synthesis in response to hypercapnia at this time, as monitored by cortical periarachnoid CSF prostanoids. Thus, returning prostanoid synthesis in response to hypercapnia could only be detected in about one third of the piglets examined at 3 h after indomethacin treatment. DISCUSSION The present study found that in newborn pigs i.v. administration of indomethacin inhibits dilation of pial arterioles to topical application of arachidonic acid and to hypercapnia, as reported previously. The inhibitions by indomethacin of vasodilations to both topical arachidonic acid and hypercapnia are lost by 3 h posttreatment, at which time vasodilations to both these stimuli are similar to those before indomethacin treatment. Repeat treatment with indomethacin after return of responses blocks the vasodilation to both stimuli again. The possibility of short duration of cerebral vascular effectiveness of indomethacin when administered systemically, as reported here, needs to be considered both when it is used as a probe for understanding contributions of PGH synthase products to control of cerebral circulation and when it is used therapeutically in attempts to alter the newborn cerebral circulation.
Demonstration of the functional significance of a relationship between a purported mediator and a response must include either inhibition of the synthesis of the mediator, scavenging of the mediator, or receptor blockade. Many hypothesized physiologic roles for prostanoids in control of cerebral circulation involve dilator effects, but effective receptor blockers for dilator prostanoids do not exist, and effective removal is not possible. Therefore, much information related to the functional significance of prostanoids is from experiments using inhibitors of PGH synthase. The most frequently used inhibitor is indomethacin, a compound that can effectively inhibit cerebral synthesis of prostanoids when adequate doses are used (2) . In adult humans, indomethacin given intramuscularly rapidly (within 30 min) enters the CSF, demonstrating the ability to cross the bloodbrain barrier (1). The ability of indomethacin to cross the bloodbrain barrier may be greater than other nonsteroidal antiinflammatory drugs because, although also strongly protein bound, the free indomethacin in plasma is greater than the free levels of others with the exception of salicylates (8) . In newborn pigs (4, 5), and apparently newborn humans (10) (11) (12) , hypercapnic cerebral vasodilation is reduced or abolished by indomethacin. This finding, coupled with measurements of cerebral synthesis of prostanoids induced by hypercapnia (4, 13) and the inability of radical scavengers to alter the responses (14) , suggests that pros-tanoids play a role in hypercapnic cerebral vasodilation in newborn pigs and human infants. Similarly, studies in adult primates, rats, and gerbils found inhibition of hypercapnic vasodilation after indomethacin (1 5-17). On the other hand, some investigators using rabbits, dogs, and cats were unable to detect an effect of indomethacin on hypercapnic cerebral vasodilation (18) (19) (20) (21) (22) , whereas others reported inhibition of hypercapnic cerebral vasodilation after indomethacin in these same three species (23) (24) (25) (26) (27) .
A report on piglets that examined changes in blood flow to the brain in response to hypercapnia indicated that vasodilatory responses to hypercapnia that are abolished by indomethacin return within 2 h after indomethacin treatment (9). Such findings suggest PGH synthase inhibition by indomethacin wears off quickly, or another effect of indomethacin unrelated to PGH synthase inhibition contributed to the decreased vasodilation in response to hypercapnia. The present study compared the return of responses to hypercapnia with the return of responses to the prostanoid precursor, arachidonic acid, as an index of activity of PGH synthase. We found that both began to return at 2 h, although only the response to hypercapnia was significant. By 3 h after indomethacin treatment, responses to both hypercapnia and exogenous arachidonic acid had returned completely to the preindomethacin levels. Furthermore, retreatment with indomethacin again totally abolished vasodilation to both stimuli, suggesting return of responses was due not to alternative mechanisms of vasodilation that were not affected by indomethacin but to insufficient residual indomethacin.
Although indomethacin did not inhibit fractional increases in prostanoids caused by arachidonic acid treatment at 3 h posttreatment, the decreases in baseline prostanoid concentrations were sustained and the absolute levels of 6-keto-PGF,,, and PGEl achieved upon treatment with arachidonic acid were less 3 h after indomethacin treatment than before. Such a finding coupled with complete return of vasodilation in response to arachidonic acid by 3 h could suggest that recovery of prostanoid synthetic capacity by vascular cells returns more quickly after indomethacin treatment than does this capacity by the rest of the brain. Such selective return would allow return of prostanoid synthesis and dilator responses by the vasculature, whereas cortical CSF prostanoids were reduced because the contribution by other cell types (neurons and/or glia) remained inhibited. Although such a selective return of synthesis in the vasculature would explain the present data, no other data to support this hypothesis are available. Further complicating the interpretations of these data is the inability to detect return of significant increases in cortical periarachnoid prostanoids in response to hypercapnia 3 h after indomethacin treatment. Dilation to arachidonic acid, along with significant conversion of arachidonic acid to prostanoids 3 h after indomethacin treatment, indicates that some PGH synthase activity has returned. Therefore, because the hypercapnic vasodilation returned coincidently with the ability of arachidonic acid to produce dilation and to be converted to prostanoids, it seems reasonable to propose that this returning PGH synthase activity is suficient to facilitate vasodilation to hypercapnia, even though detectable increases in the CSF over the brain surface did not occur. Such findings clearly demonstrate that cerebral prostanoids do not act as hormones that accumulate in cortical CSF whereby dilation is produced. The mechanism by which prostanoids appear to facilitate hypercapnia-induced cerebral vasodilation remains unclear, but the present data may imply that only localized, limited synthesis is necessary. It remains possible that, in addition to inhibiting PGH synthase, another effect of indomethacin could contribute to the ability of this compound to block dilation to exogenous arachidonic acid and hypercapnia. Indomethacin has been reported to inhibit cyclic AMP-dependent protein kinase (28) . Because CAMP-dependent protein kinase probably is involved in prostanoid-induced vasodilation, such inhibition could amplify the ability of indomethacin to eliminate responses.
The high degree of effectiveness of indomethacin at 5 mg/kg to block PGH synthase that we report seems to contrast with the very weak effect reported by Chemtob et a/. (29) . In their piglets, indomethacin (3 mg/kg) had only slight effects on arterial and sagittal sinus prostanoids, suggesting the effect would have been even less on conversion of arachidonic acid to prostanoids on the brain surface. The difference is unlikely to be the result of the lower dose (3 mg/kg) used because we found previously that 2 mg/kg decreased cortical periarachnoid prostanoids markedly and inhibited conversion of topically applied arachidonate to prostanoids (2). It is also unlikely that indomethacin is affecting cortical periarachnoid prostanoids more than plasma prostanoids, because we found indomethacin at 5 mg/kg decreased plasma 6-keto-PGF,,, to nondetectable levels by 30 min after administration (4) and blocked the increase in net cerebral 6-keto-PGF,,, production (sagittal sinus minus arterial times flow) caused by hypotension (30). We do not know the reason the measured plasma prostanoid levels did not decline more with indomethacin treatment of 3 mg/kg in the report of Chemtob et a/. At 10 mg/kg, they also found plasma levels of prostnoids to be reduced to very low or nondetectable concentrations.
Whether the duration of effectiveness of indomethacin on the cerebral circulation of the newborn human infant is equally short as that on the piglet is not known. However, inasmuch as very low doses of indomethacin are used in treating newborn infants, the likelihood that the effects on the cerebral circulation are much shorter than previously assumed is great. Indomethacin has been reported to have beneficial prophylactic effects in prevention and/or reduction of severity of intraventricular/periventricular hemorrhage in premature babies (3 1-33). One proposed mechanism for such effects is reducing the fluctuation in cerebral blood flow in response to changes in carbon dioxide and blood pressure changes. The possibility that any such effects could be lost within hours after administration must now be considered.
